drugset / Trial / NCT02381652

Repeat Injection of Cingal® for Osteoarthritis of the Knee

NCT02381652

Phase 3 Completed 242 enrolled Anika Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety of an injection of Cingal® in subjects with Osteoarthritis (OA) of the knee who participated in Cingal 13-01, and who received either a Cingal, Monovisc, or saline injection in the 13-01 study. The safety evaluation will be done by a through examination of the incidence of adverse events and physical examination of the knee.

Timeline

Start
2015-02
Primary completion
2015-04
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyaluronic Acid Other / unclassified 88 mg Other
Subject Triamcinolone Hexacetonide Other / unclassified 18 mg Other

Indications